Enhancing factor (EF), a growth factor modulator, is the mouse homologue of human secretory group II phospholipase A 2 . EF exhibits growth-promoting activity in vitro, in the presence of epidermal growth factor, and also brings about phenotypic transformation of normal cells. In order to ascertain the role of EF in vivo, a human keratin-14 promoter was used to drive the expression of EF ectopically to squamous epithelial cells. The founder mouse and its progeny showed abnormal whiskers and a scaly, beaded tail. In these mice, keratinization pattern of the epidermis was disturbed and parakeratosis and acanthosis were noted. The transgenic mice, TgK14-EF, expressed EF in the suprabasal layers of tail epidermis as well as in the epithelial cells of hair follicle and sebaceous glands of skin. Expression of EF along with hyperplasia was also observed in other squamous epithelia such as buccal mucosa, tongue and oesophagus. TgK14-EF mice homozygous for the transgene showed delayed and scanty hair growth although the mice were healthy and fertile. The hemizygous TgK14-EF mice were sensitive to a twostage chemical carcinogenesis and developed a higher number of papillomas than their normal littermates over the course of the experiment. The conversion rate of papilloma to carcinoma was two fold higher in the transgenic mice.
Introduction
Enhancing factor (EF), the mouse homologue of human type II secretory phospholipase A 2 (sPLA 2 ), was purified to homogeneity from mouse intestines, based on its ability to increase the binding of epidermal growth factor (EGF) to A431 cells in the radio-receptor assay (Deo et al., 1983; Mulherkar et al., 1993a, b) . Using specific, high-titre polyclonal antibodies to EF, expression of the gene was demonstrated to be predominantly in the Paneth cells in the intestinal villi, adjacent to the stem cell population (Wagle et al., 1989 , Mulherkar et al., 1991 . EF expression was also seen in the proliferative compartment in the outer root sheath of active hair follicles in newborn mouse skin (Mulherkar et al., 1991) . It was proposed that EF acts as a growth factor modulator of EGF (Mulherkar and Deo, 1986) .
EF/sPLA 2 is a dual function molecule exhibiting phospholipase and enhancing activities residing in two separate domains (Kadam and Mulherkar, 1999) . sPLA 2 is known to hydrolyse the sn-2 fatty acid from glycerophospholipids and plays a role in a variety of physiological functions (Murakami et al., 1997) . Higher levels of sPLA 2 have been detected in the plasma and synovial fluids of patients with a variety of inflammatory conditions such as rheumatoid arthritis, acute pancreatitis, Crohn's disease and endotoxic shock as well as in various cancers (Kaiser et al., 1990) . Expression of sPLA 2 /EF has also been shown to reduce the number of intestinal polyps in the min mouse model for intestinal neoplasia, wherein mice null for EF activity because of a frame-shift mutation in the coding region are more susceptible to the effect of min mutation (Kennedy et al., 1995; Cormier et al., 1997) . In the recent past, six new mouse sPLA 2 s structurally related to mouse type II sPLA 2 s have been identified (Gelb et al., 2000) . With the expanding super-family of PLA 2 , characterization of all the PLA 2 isoforms is necessary to ascertain if there is any functional redundancy among the different isoforms and also whether they possess any as yet unidentified functions/activities. EF, in the presence of EGF, has been shown to give cells a growth advantage in vitro, and also brings about phenotypic transformation of normal cells by inducing anchorage-independent growth in the presence of EGF (Mulherkar and Deo, 1986) . In order to study the interaction of EF with EGF in vivo, we resolved to generate transgenic mice expressing EF in the squamous epithelial cells by subcloning EF cDNA under a human keratin-14 promoter. EGF receptors have been detected in the proliferative zones of the epidermis, sebaceous glands and hair follicles (Green et al., 1983) , where expression of the transgene under the keratin-14 promoter would be expected. Also, based on the in vitro property of EF in bringing about transformation of normal cells in the presence of EGF, we subjected the transgenic mice to a two-stage chemical carcinogenesis. K14-EF transgenic mice were more sensitive to skin cancer compared to their normal littermates.
Results

Construction of K14-EF expression vector
In order to express EF in the skin, EF cDNA was subcloned under the human keratin-14 promoter that has been used successfully to express transgenes in the epidermis (Vassar et al., 1989) . A 720 bp EF insert from pRc/CMV-EF carrying the complete coding region along with the Kozak sequence and the 3 0 UTR was inserted into the BamH1 site of pGEM3Z-K14 vector to create pK14-EF ( Figure 1a ). The functional elements from the construct were excised by EcoR1/HindIII digestion, transfected into HeLa and fetal buccal mucosa (FBM) cells to confirm its specificity (data not shown).
Generation and characterization of transgenic K14-EF mouse lines
The purified EcoRI/HindIII fragment was microinjected into the male pronuclei of fertilized eggs of FVB/n females crossed with BDF males and transferred into the oviduct of CD-1 pseudopregnant females. The offspring were examined for any aberrant phenotype and analysed for integration of the transgene by PCR and Southern hybridization. One of the pups in a litter of nine pups was smaller in size and showed a peculiar beaded tail. Tail biopsies were taken on day 21, genomic DNA isolated and subjected to PCR using K14-specific forward primer and EF-specific reverse primer. Two of the mice, 700 and 705, both males, showed presence of the 450 bp band (Figure 1b) . DNA from these two putative transgenic mice along with one of their normal littermates was digested with BamH1 as well as EcoRV and subjected to Southern analysis. Both these mice showed presence of the 1.9 kb band when the DNA was cut with EcoRV, which cuts inside the expression cassette (Figure 1a , c) and confirmed the presence of the transgene. However, intensity of the 1.9 kb fragment in the Southern blot (Figure 1c ) indicated that the copy number in Tg700 was much higher than that in the second transgenic mouse, Tg705.
Tg700 and Tg705 were crossed with either wild-type FVB/n females or their nontransgenic siblings, in order to obtain the F1 progeny. When a large number of pups born to Tg700 were screened by PCR, more than 80% were positive for the transgene, whereas only 43% of the pups born to Tg705 were PCR positive. This indicated that in Tg700 the transgene was integrated in more than one chromosome. The 1.9 kb signal obtained after Southern hybridization of DNA from F1 pups sired by Tg700 mouse was of different intensities in pups from the same litter (Figure 1d ). This was attributed to a higher copy number of the transgene integrated at one site on one chromosome and fewer copies on another chromosome, in Tg700 and its progeny. The signal obtained in Tg705 and its progeny was comparable to the low-copy number mice in Tg700 progeny (data not shown).
Phenotype of the K14-EF transgenic mice
Although the transgenic mice were healthy and fertile, one of the founder mice, Tg700, exhibited several phenotypic peculiarities. Tg700 and its progeny lacked whiskers compared to the wild-type mice, indicating a problem in the hair production in the vibrissal follicles (data not shown). However, the body hair appeared normal demonstrating that normal pelage follicles contribute to hair growth.
From the time of birth, Tg700 as well as its F1 progeny were smaller in size and showed a mildly serrated, scaly tail. With time, the serrations became more prominent, appearing beaded and necrotic at the tip (Figure 2a-d) . By the end of 8 weeks, the tail appeared normal except for a swollen, bulbous region at its tip with a proximal constriction (Figure 2d) . Some of the transgenic mice also showed thickened ear skin and hind paws and developed opacity of the cornea (data not shown). Neither Tg705 nor any of the low-copy member progeny of Tg700 showed any abnormal phenotype. Henceforth, transgenic mice will refer to high-copy transgenic mice only.
Interestingly, when two F1 transgenic mice were crossed, in 25% of the F2 progeny, besides being whiskerless and possessing an abnormal tail, the mice also showed delayed appearance of body hair. At birth, the mice were hairless (data not shown). Hair appeared after 30 days and the hair coat was comparable to normal mice. However, there was gradual hair loss and most of the hair was lost by 15 days, again appearing hairless. The new hair growth was sparse compared to normal mice. This cyclic hair growth and hair loss continued throughout the life of the mice. This phenomenon appears to be associated only with mice homozygous for the high-copy transgene. To confirm the homozygosity, hairless F2 mice were backcrossed to wild-type FVB/n mice. All the progeny of this cross displayed lack of whiskers and beaded tail, and were positive for the high-copy transgene, confirming the homozygous nature of the F2 mice. The mice homozygous for the low-copy number transgene did not show any phenotypic characteristics.
Histology of tissue sections from transgenic and wild-type mice
A cross-section of the tail was taken for histology from wild-type, hemizygous F1 and homozygous F2 mice. The epidermis of the tail skin of the transgenic mice had Transgenic mice expressing enhancing factor in epidermis R Mulherkar et al a higher number of nucleated squamous cell layers as compared to the controls (Figure 3 ). Since proliferation is restricted to basal epithelium in normal skin, a proliferation marker-Ki67 was used to identify the proliferative regions in the multilayered epidermis in the transgenic mouse skin. Strong nuclear staining was observed in the basal layers as well as the suprabasal layers in the multilayered tail skin of transgenic mouse ( Figure 3B -b), whereas faint staining was seen in a few nuclei in the basal layers of wild-type mouse skin ( Figure 3B-d) . The epidermis and the hair follicles in the tail skin from nontransgenic littermates were 2-4 nucleated cell layers thick ( Figure 3B-d ). In the transgenic mice, the tail skin epidermis was 9-13 
Expression of the EF protein
In tail epidermis of transgenic mice, positive staining for EF was observed in the suprabasal cell layers of the epidermis ( Figure 3A -b,c) and in hair follicles and sebaceous glands, whereas no staining was seen in the skin of normal littermates ( Figure 3A-a) . Tail section of the F2 transgenic mice, which showed alopecia, expressed excessive EF protein in the acanthotic epidermis as well as in the enlarged sebaceous glands ( Figure 3A c). Overexpression of EF and a thickened epidermis was best appreciated in regions that normally had a relatively thick epidermis and where the hair follicle density was low. EF expression was also seen in the squamous epithelial cells of hair follicles and sebaceous glands of dorsal skin and snout, in the epidermis of tongue, buccal mucosa and oesophagus (data not shown).
The presence of EF correlated with epidermal hyperplasia in all mice. Tg705, its progeny and the low-copy number progeny of Tg700, did not show the presence of EF protein in the tail. Our results suggest that in the K14-EF transgenic mice, overexpression of EF in the proliferative zones of squamous epithelia acts as a mitogen and results in an increased number of cell layers leading to squamous epithelial hyperplasia and acanthosis.
Chemical carcinogenesis in K14-EF transgenic mice
Hemizygous transgenic mice along with their normal littermates as well as wild-type mice were taken in this Transgenic mice expressing enhancing factor in epidermis R Mulherkar et al study. None of the wild-type FVB/n mice treated with DMBA-TPA (9,10-dimethylbenz(a)anthracene-12-Otetradecanoylphorbol-13 acetate) developed tumours during the course of the experiment. The time required for the appearance of the first squamous papilloma was 7 weeks in TgK14-EF mice compared to 9 weeks in normal siblings (Table 1) . CD-1 mice, which are sensitive to chemical carcinogenesis, also developed tumours by seventh week. By 15 weeks of treatment, 86% of TgK14-EF mice and 78% of normal littermates had developed tumours, while at 25 weeks after TPA treatment, 93% of the TgK14-EF mice had developed squamous papillomas compared to 67% of normal littermates treated similarly (Figure 4a ). TgK14-EF mice developed significantly higher number of papillomas per mouse than their normal littermates over the course of the experiment (Table 1, Figure 4b ). Although 100% of CD-1 mice developed papillomas by 15th week, the average number of papillomas at that time point was only 4.8 per mouse. TgK14-EF mice treated with 4-nitroquinoline N-oxide (4NQO) in the progression phase showed a two fold increase in the rate of conversion of papilloma to carcinoma at 44 weeks when compared to normal littermates (63 vs 33%). However, the increase was not statistically significant.
The papillomas and carcinomas were subjected to immunostaining using antibodies to EF. In transgenic mice, expression of EF was seen in the squamous epithelial cells of both papillomas (Figure 5b, c) and carcinomas (Figure 5e, f) . Other histopathological lesions induced by the above protocol were trichoepithelioma, which is a benign epithelial tumour of the hair follicles, and fibrosarcoma -a malignant tumour of mesenchymal origin (data not shown), both of which showed positive staining for EF.
Discussion
EF, the mouse homologue of human type II sPLA 2 , was purified to homogeneity, in our laboratory, as a growth factor modulator as it increases the binding of EGF to A431 (Deo et al., 1983) . EF, in the presence of EGF, has been shown to give cells a growth advantage in vitro (Mulherkar and Deo, 1986) . This prompted us to generate transgenic mice expressing EF under a human keratin-14 promoter to study the effect of EF expression in vivo in epidermal tissue where EGF is known to play a role. Also, EF played a role in the transformation of normal cells in vitro (Mulherkar and Deo, 1986) , leading us to study the effect of chemical carcinogens in the transgenic mouse skin.
In the present study, one of the founder mice, Tg700, had a beaded tail and lacked whiskers whereas the other founder, Tg705, appeared normal. By Southern hybridization Tg700 was found to have a higher transgene copy number as compared to Tg705, with at least two integration sites that segregated in the F1 generation. Expression of EF and the phenotype appeared to be Transgenic mice expressing enhancing factor in epidermis R Mulherkar et al associated with high-copy number genotype. The transgene in Tg705 did not express, which could be because of a (i) low-copy number or (ii) inactivation because of the site of integration. Histological examination and immunostaining of tail epidermis as well as epidermis of the snout, tongue, buccal mucosa and oesophagus of transgenic mice revealed expression of EF unexpectedly in the suprabasal layers rather than in the basal layers. It has been reported earlier that it is the repressor elements, rather than the transcriptional activators, that decide the activity of specific keratin promoters (Vassar et al., 1989; Jiang et al., 1991) . Hence, this alteration in the pattern of K14 promoter activation in Tg700 could be because of alteration in the chromatin structure around the transgene and masking of the K14 repressor elements thus resulting in aberrant expression of the transgene. In the Tg700 mice the squamous epithelia expressing EF were hyperplastic as compared with the control. This could be because of the ability of EF to make EGF available to the cells, and thereby resulting in hyperproliferation. EGF when injected into neonatal mice has been shown to promote epidermal growth, thickening and keratinization (Cohen and Elliott, 1963) . This effect appeared to be mimicked in K14-EF transgenic mice, especially in those regions where body hair was sparse such as tail, snout and paws.
EGF receptors have been detected on the epithelial cells overlying the basement membrane of the epidermis, sebaceous gland and regions of the hair follicle all of which have a proliferative capacity (Green et al., 1983) . In the transgenic mice generated, expression of EF was seen in these regions and hence it is likely that a functional link can be established between EF/sPLA 2 , EGF and EGF receptors.
There is compelling evidence that a large number of growth factors and their receptors, including EGF and TGF-a, play a crucial role in hair fibre formation by regulating stem cells and the progenitors. Transgenic mice expressing EGF or EGF-R family of molecules under a keratin-14 or keratin-5 promoter, both active in the proliferating layers of epidermis, have led to overexpression in the basal layer of epidermis resulting in alopecia, hyperplasia of epidermis, follicular hyperplasia, sebaceous gland enlargement and dramatic disruption in hair follicle morphogenesis (Vassar and Fuchs, 1991; Xie et al., 1998; Kiguchi et al., 2000) . Expression of the EF transgene was seen in the snout epidermis, suprabasal layers of the tail epidermis as well as in the outer root sheath of hair follicles and skin Transgenic mice expressing enhancing factor in epidermis R Mulherkar et al sebaceous glands in the TgK14-EF mice resulting in a similar phenotype as the mice expressing EGF or EGFreceptor family molecules in the skin.
Absence of whiskers in the transgenic mice indicates disruption in the signalling of the vibrissal follicles. Recently, Oshima et al. (2001) have shown that the regulation of whisker growth involves a precise control of stem cells and their trafficking. Although the pelage follicles appeared normal in the TgK14-EF mice, they were abnormal in the homozygous mice. TgK14-EF mice in the F2 generation, homozygous for the highcopy number transgene, showed aberrant hair growth with intermittent alopecia. This indicates that EF/sPLA 2 either influences or interferes with EGF receptor signalling responsible for control of hair growth.
The severity of the phenotype in F2 homozygous (for high-copy number) mice could be because of dosage effect. The dosage effect of transgene expression has been reported to affect the severity of the phenotype. Transgenic mice expressing dominant-negative EGF-R in the skin showed curly whiskers and delayed appearance of hair and later exhibited alopecia (Murillas et al., 1995) . Some of these mice showing lesser expression of the protein had a milder phenotype, whereas homozygous mice expressing more protein showed a more severe phenotype. Grass et al. (1996) have reported transgenic mice expressing human group II PLA 2 under its own promoter. The founder mice developed a disorder of the skin resulting in epidermal hyperplasia, hyperkeratosis and almost complete alopecia that was comparable to the phenotype of the F2 generation of K14-EF transgenic mice reported here. In spite of the fact that PLA 2 plays a role in inflammation, the human PLA 2 transgenic mice did not develop any overt inflammatory condition. The same was true for K14-EF transgenic mice. The only sign of inflammatory reaction in K14-EF transgenic mice was the beaded, scaly oedematous tail.
Since TgK14-EF mice showed expression of EF in the proliferating layers of all squamous epithelia, and as these also showed hyperplasia, the mice were subjected to a two-stage chemical carcinogenesis protocol to determine their sensitivity to skin tumorigenesis. Members of the EGF receptor family have been shown to act synergistically with TPA through EGF-R overstimulation and development of DMBA-initiated tumours (Shibata et al., 1997) . Kiguchi et al. (2000) have reported over expression of wild-type rat erb-B-2 in the basal layer of epidermis leading to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. These transgenic mice were hypersensitive to the proliferative effects of TPA and were more sensitive to a two-stage carcinogenesis.
When TgK14-EF mice were subjected to a two-stage skin carcinogenesis protocol, a statistically significant increase in tumour occurrence and a reduction in time to tumour formation, compared to normal littermates, were achieved (Table 1) . It is noteworthy that TPA application leads to K14 expression in the outer root sheath of the hair follicle (Roop et al., 1988) . This would presumably lead to overexpression of EF in the hair follicles where it is already seen in the transgenic mice. Taylor et al. (2000) have reported that the bulge region of hair follicle, which is the part of the outer root sheath, harbours the stem cells that can form not only the follicle but also the epidermis. These stem cells are thought to be the major targets of tumour initiating agents by chemical carcinogenesis (Morris et al., 1986; Lavker et al., 1993) . Tumour promotion involves clonal expansion of initiated cells resulting in the formation of increased number of papillomas and few carcinomas. Expression of EF in the hair follicles of the K14-EF mice might propel the squamous cells of the skin along the hyperplasia -carcinoma pathway by giving cells an additional impetus to proliferate. This additive effect of EF overexpression may have an effect both in early and late phases of tumour evolution. This would also explain the increased incidence of papillomas and also of the twofold increase observed in the rate of conversion of papilloma to carcinoma by application of 4NQO in the progression phase in this study.
The TgK14-EF mice are phenotypically similar to transgenic mice overexpressing EGF/EGF-R that could be explained by the action of EF in trapping EGF and making EGF available in the epidermis. Thus, the K14-EF transgenic mouse would be a useful candidate for studying (i) the role of EF-EGF in hair follicle morphogenesis and (ii) the effect of EF on tumour formation by chemical carcinogens and validate their use as experimental models in studies on squamous cell carcinomas.
Materials and methods
Vector construction
The vector, pK14-EF, was constructed using the keratin-14 expression cassette pGEM3Z-K14 (a kind gift from Dr Elaine Fuchs, Chicago, USA). The cassette vector contains a 2 kb fragment of human K14 promoter/enhancer and 500 bp of 3 0 flanking sequence including a K14 polyadenylation signal. The EF cDNA was PCR amplified using primers EFH5 0 and EFX3 0 with plasmid pRc/CMV-EF as template as described earlier (Mulherkar et al., 1993b; Kadam and Mulherkar, 1999) . The 720 bp PCR product was ligated to the vector at the BamHI site after filling in the ends in both the vector and the EF insert. Orientation of the insert was confirmed by restriction digestion and Southern hybridization. The resulting recombinant plasmid was termed as pK14-EF. Tissue-specific expression of pK14-EF was checked in vitro on HeLa and FBM cell lines (data not shown).
Generation of transgenic mice
The K14-EF expression cassette was excised by EcoR1/HindIII digestion of pK14-EF. Since the vector backbone and the insert were of similar sizes, the vector backbone was further cut into smaller fragments using PvuI. The 3.2 kb band was gelpurified and the final concentration was adjusted to 5 ng/ml in 10 mm Tris with 0.1 mm EDTA, pH 8.0, and used for microinjection. The DNA was filtered through a Millex-HV, 0.45 mm filter unit (Millipore), before microinjection. Fertilized eggs for microinjection were obtained by crossing FVB/n females with BDF-1 males. The DNA was microinjected into the male pronucleus of the single-cell embryo using Transjector (Eppendorf, Germany). Pseudopregnant CD-1 females were used as recipients. All animals were housed in our accredited Institute animal facility in accordance with the institutional animal care policies.
Screening by PCR and Southern hybridization
Transgenic mice were identified by PCR using K14-EF-specific primers on DNA extracted from tail biopsies as well as by Southern hybridization of EcoRV-digested genomic DNA. The PCR primers used were K14-EF-forward 5 0 AAGTGC-CAGACCCGCCCCCTAC 3 0 and EFM38-reverse 5 0 ATT-CAGCGGCGGCTTTATCG 3 0 , and the amplified product was subjected to sequencing using Sequanase kit (USB, USA) for confirmation. For Southern hybridization, 20 mg DNA from each mouse was cut with appropriate restriction enzyme and blotted onto nitrocellulose membrane (Hybond C extra, Amersham). a 32 P-dCTP-labelled EF cDNA or K14-EF insert was used as a probe.
Immunohistochemistry
A small piece of the tail from two putative transgenic mice, Tg700 and Tg705 (which were positive in PCR) and their siblings was fixed in Bouins' fixative for 2 h, washed extensively with 70% alcohol and paraffin embedded. Sections (5 mm) were subjected to immunohistochemistry using polyclonal antiserum to EF (1 : 10 000 dilution) and ABC kit from Vectastain (Vector Laboratories, USA), as described earlier (Mulherkar et al., 1991) . Tail sections were also stained with antibodies to Ki67 (M-19, Santa Cruz Biotechnology) at a dilution of 1 : 50 after antigen retrieval for 15 min in microwave and developed using Vectastain kit. Control slides were treated with appropriate normal serum. Sections were counterstained with haematoxylin.
Chemical carcinogenesis protocol
The back skin of 6-8 weeks old transgenic mice (hemizygous), their normal sibling, CD-1 mice and wild-type FVB/n mice (n ¼ 9-15 mice per group) was shaved with an electric clipper. A volume of 100 nmol DMBA dissolved in 100 ml acetone was applied topically to the shaved back of each mouse. At 1 week after DMBA initiation, 5 nmol TPA in 100 ml acetone was applied twice a week for 25 weeks. In experiments on tumour progression, papillomas were induced by standard DMBA-TPA protocol as described above. After the treatment-free period of 5 weeks, the back skin was treated twice a week with 250 mg of 4NQO for 14 weeks. The number of papillomas as well as the number of papillomas converting to carcinomas was recorded every week. At the end of the experimental period, tumour tissues that is papillomas at 25 weeks and carcinomas (occurring as downward invading lesions) at 44 weeks were excised, fixed in Bouins' fluid and were processed for routine histopathology and immunostaining as described above.
Statistical analysis
The incidence of papilloma/carcinoma (expressed as percentage) was calculated as (P n /C n )/N n , where P n /C n are the number of animals showing papilloma/carcinoma and N n the total number of animals during the nth week. The incidence of papilloma/carcinoma and its conversion for the transgenic mice and normal siblings groups were compared using the Fisher exact test. The mean number of papilloma/mouse for the two groups was compared using Mann-Whitney test. Statistical significance is reported using two-tailed probability values.
